Publication of the prospectus
14 Outubro 2009 - 3:00AM
UK Regulatory
TIDMCRYO
RNS Number : 7202A
Cryo-Save Group NV
14 October 2009
This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Japan, South Africa or any jurisdiction in which the
same would be unlawful. This announcement is not an offer of securities in the
United States, Canada, South Africa, Australia, Japan or any other jurisdiction.
14 October 2009
Cryo-Save Group N.V.
("Cryo-Save" or "the Company")
Publication of the prospectus and listing on Euronext Amsterdam
Cryo-Save Group N.V. (AIM: CRYO, "Cryo-Save" or "the Company"), Europe's leading
stem cell bank, announces that it has published today its prospectus as approved
by the Netherlands Authority for the Financial Markets (Stichting Autoriteit
Financiële Markten, "AFM") regarding the additional Euronext Amsterdam listing.
The Company expects that the Euronext Amsterdam listing will become effective
and that dealings in its shares on Euronext Amsterdam will commence on Thursday
22 October 2009.
The prospectus is generally available free of charge at the Company's offices in
Zutphen, the Netherlands and can be downloaded from the Company's website,
www.cryo-savegroup.com.
The information contained herein is not for publication or distribution,
directly or indirectly, in or into the United States of America (including its
territories and possessions, any State of the United States and the District of
Columbia). These materials do not contain or constitute an offer for sale or the
solicitation of an offer to purchase securities in the United States or any
other jurisdiction. The securities mentioned herein have not been and will not
be registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and may not be offered or sold in the United States absent registration
under the Securities Act or an available exemption from, or transaction not
subject to, the registration requirements of the Securities Act.
This announcement is not a prospectus. In connection with the admission of the
shares in the capital of the Company to trading on Euronext Amsterdam by NYSE
Euronext, a prospectus has been made generally available. Copies of the
Prospectus are available at no cost through the website of the Company
(www.cryo-savegroup.com) and the website of Euronext Amsterdam (Dutch residents
only) and by sending a request in writing to the Company at its business
address: IJsselkade 8, 7201 HB Zutphen, the Netherlands.
+-------------------------------------+----------------------------------+
| For further details: | |
+-------------------------------------+----------------------------------+
| | |
+-------------------------------------+----------------------------------+
| Cryo-Save Group | + 31 (0) 575 548998 |
+-------------------------------------+----------------------------------+
| Marc Waeterschoot, Chief Executive | |
| Arnoud van Tulder, Chief Financial | |
| Officer | |
+-------------------------------------+----------------------------------+
| | |
+-------------------------------------+----------------------------------+
| Daniel Stewart & Company plc | + 44 (0) 20 7776 6550 |
+-------------------------------------+----------------------------------+
| Simon Leathers | |
+-------------------------------------+----------------------------------+
| | |
+-------------------------------------+----------------------------------+
| College Hill | + 44 (0) 20 7457 2020 |
+-------------------------------------+----------------------------------+
| Adrian Duffield/Rozi Morris | |
+-------------------------------------+----------------------------------+
About Cryo-Save
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in
Europe and one of the fastest growing in the world. Driven by its international
business strategy, Cryo-Save is now represented in 38 countries on three
continents and has state-of-the-art processing facilities in Belgium, Germany,
Dubai, India and France (under construction).
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to
make an important contribution to conquer possible life-threatening diseases in
the future. As a service to the public, Cryo-Save offers a Cost-free Family
Donation Programme, free of charge, to families wishing to store their newborn's
umbilical cord blood stem cells for a family member diagnosed with a
life-threatening disease treatable by stem cells. The company is committed to
further improve stem cell cryopreservation techniques, by participating in
European Commission funded projects, in Universities and Hospitals.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PDIDGMMGVFNGLZM
Cryo-Save (LSE:CRYO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cryo-Save (LSE:CRYO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Cryo-Save da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Cryo-Save